SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Want to cut your energy bills? Here’s how five experts are doing it 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
 & Lead Plaintiff Deadline: March 13, 2017 - EconoTimes)
NEW YORK, March 08, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE:NVO) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Novo American Depositary Receipts ("ADR") between April 30, 2015 and October 27, 2016, both dates inclusive (the “Class Period”). Investors with losses in excess of $1 million are advised to join this case by visiting the firm’s site: http://www.bgandg.com/nvo.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Novo reported materially false and misleading Company earnings and predications in that they were inflated through the collusive price fixing of Novo’s insulin drugs. The Complaint also alleges that Novo misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/nvo or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. Investors with losses in excess of $1 million in Novo have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
